Cargando…
Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties
Paroxysmal nocturnal hemoglobinuria (PNH) is an intriguing disease that can pose many difficulties to physicians, as well as to hematologists, who are unfamiliar with it. Research regarding its pathophysiologic, diagnostic, and therapeutic aspects is still ongoing. In the last ten years, new flow cy...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957780/ https://www.ncbi.nlm.nih.gov/pubmed/33804461 http://dx.doi.org/10.3390/jcm10050948 |
_version_ | 1783664728100306944 |
---|---|
author | Fattizzo, Bruno Serpenti, Fabio Giannotta, Juri Alessandro Barcellini, Wilma |
author_facet | Fattizzo, Bruno Serpenti, Fabio Giannotta, Juri Alessandro Barcellini, Wilma |
author_sort | Fattizzo, Bruno |
collection | PubMed |
description | Paroxysmal nocturnal hemoglobinuria (PNH) is an intriguing disease that can pose many difficulties to physicians, as well as to hematologists, who are unfamiliar with it. Research regarding its pathophysiologic, diagnostic, and therapeutic aspects is still ongoing. In the last ten years, new flow cytometry techniques with high sensitivity enabled us to detect PNH clones as small as <1% of a patient’s hematopoiesis, resulting in increasing incidence but more difficult data interpretation. Particularly, the clinical significance of small PNH clones in patients with bone marrow failures, including aplastic anemia and myelodysplastic syndromes, as well as in uncommon associations, such as myeloproliferative disorders, is still largely unknown. Besides current treatment with the anti-C5 eculizumab, which reduced PNH-related morbidity and mortality, new complement inhibitors will likely fulfill unmet clinical needs in terms of patients’ quality of life and better response rates (i.e., responses in subjects with C5 polymorphisms; reduction of extravascular hemolysis and breakthrough hemolysis episodes). Still, unanswered questions remain for these agents regarding their use in mono- or combination therapy, when to treat, and which drug is the best for which patient. Lastly, long-term safety needs to be assessed in real-life studies. In this review, we describe some clinical vignettes illustrating practical aspects of PNH diagnosis and management; moreover, we discuss recent advances in PNH diagnostic and therapeutic approaches. |
format | Online Article Text |
id | pubmed-7957780 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-79577802021-03-16 Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties Fattizzo, Bruno Serpenti, Fabio Giannotta, Juri Alessandro Barcellini, Wilma J Clin Med Review Paroxysmal nocturnal hemoglobinuria (PNH) is an intriguing disease that can pose many difficulties to physicians, as well as to hematologists, who are unfamiliar with it. Research regarding its pathophysiologic, diagnostic, and therapeutic aspects is still ongoing. In the last ten years, new flow cytometry techniques with high sensitivity enabled us to detect PNH clones as small as <1% of a patient’s hematopoiesis, resulting in increasing incidence but more difficult data interpretation. Particularly, the clinical significance of small PNH clones in patients with bone marrow failures, including aplastic anemia and myelodysplastic syndromes, as well as in uncommon associations, such as myeloproliferative disorders, is still largely unknown. Besides current treatment with the anti-C5 eculizumab, which reduced PNH-related morbidity and mortality, new complement inhibitors will likely fulfill unmet clinical needs in terms of patients’ quality of life and better response rates (i.e., responses in subjects with C5 polymorphisms; reduction of extravascular hemolysis and breakthrough hemolysis episodes). Still, unanswered questions remain for these agents regarding their use in mono- or combination therapy, when to treat, and which drug is the best for which patient. Lastly, long-term safety needs to be assessed in real-life studies. In this review, we describe some clinical vignettes illustrating practical aspects of PNH diagnosis and management; moreover, we discuss recent advances in PNH diagnostic and therapeutic approaches. MDPI 2021-03-01 /pmc/articles/PMC7957780/ /pubmed/33804461 http://dx.doi.org/10.3390/jcm10050948 Text en © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Fattizzo, Bruno Serpenti, Fabio Giannotta, Juri Alessandro Barcellini, Wilma Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties |
title | Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties |
title_full | Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties |
title_fullStr | Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties |
title_full_unstemmed | Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties |
title_short | Difficult Cases of Paroxysmal Nocturnal Hemoglobinuria: Diagnosis and Therapeutic Novelties |
title_sort | difficult cases of paroxysmal nocturnal hemoglobinuria: diagnosis and therapeutic novelties |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7957780/ https://www.ncbi.nlm.nih.gov/pubmed/33804461 http://dx.doi.org/10.3390/jcm10050948 |
work_keys_str_mv | AT fattizzobruno difficultcasesofparoxysmalnocturnalhemoglobinuriadiagnosisandtherapeuticnovelties AT serpentifabio difficultcasesofparoxysmalnocturnalhemoglobinuriadiagnosisandtherapeuticnovelties AT giannottajurialessandro difficultcasesofparoxysmalnocturnalhemoglobinuriadiagnosisandtherapeuticnovelties AT barcelliniwilma difficultcasesofparoxysmalnocturnalhemoglobinuriadiagnosisandtherapeuticnovelties |